Sun Pharmaceutical Industries has announced that USFDA has granted approval for the Abbreviated New Drug Application (ANDA) to market generic Sinemet, carbidopa and levodopa tablets.These carbidopa and levodopa tablets are therapeutically equivalent to Sinemet tablets from Bristol-Myers Squibb and are available in three strengths: 10 mg / 100 mg, 25 mg / 100 mg and 25 mg / 250 mg.
These strengths of carbidopa and levodopa tablets, used in the treatment of Parkinson’s disease and syndrome, have annual sales of approximately US$ 70 million in the US.The company made this announcement after the trading hours on Wednesday, 05 November 2008.
No comments:
Post a Comment